Dr Reddys Laboratories will hold a meeting of the Board of Directors of the Company on 12 May 2026.Powered by Capital Market - Live News

Dr. Reddy`s Laboratories announced the launch of its injectable semaglutide under the brand name Obeda�, marking an important step in expanding access to advanced GLP‑1 receptor agonist�based therapy for the management of type 2 diabetes in India. Dr. Reddy`s has been the first Indian company to receive Drugs Controller General of India (DCGI) approval for generic semaglutide. This launch underscores the company`s Day‑1 entry into the segment upon patent expiry, demonstrating its readiness to serve unmet patient needs in India. Powered by Capital Market - Live News

Dr Reddys Laboratories has allotted 10,275 equity shares under ESOPs on 12 March 2026. Powered by Capital Market - Live News

Net profit of Dr Reddy`s Laboratories declined 14.42% to Rs 1209.90 crore in the quarter ended December 2025 as against Rs 1413.70 crore during the previous quarter ended December 2024. Sales rose 4.41% to Rs 8727.00 crore in the quarter ended December 2025 as against Rs 8358.60 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales8727.008358.60 4 OPM %21.6327.19 - PBDT2064.202345.70 -12 PBT1543.201874.30 -18 NP1209.901413.70 -14 Powered by Capital Market - Live News

Dr. Reddy`s Laboratories announced the launch of over-the-counter (OTC) Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7%, the generic equivalent of Extra Strength Pataday� Once-Daily Relief, in the U.S. market, as approved by the U.S. Food and Drug Administration (USFDA). Dr. Reddy`s Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% is an Antihistamine eye drop, indicated for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair and dander. Powered by Capital Market - Live News